More On

FDA issues warning about shortened cancer drug name

Agency cautions health care providers not to mix up two similarly named drugs

What’s in a name? A lot, according to a new warning from the Food and Drug Administration (FDA).

The agency on Monday alerted the public that using a shorter name for the new breast cancer drug Kadcyla may lead to confusion with another treatment. Kadcyla, which is manufactured by a subsidiary of the Roche group, is properly known as ado-trastuzumab emtansine. This is similar to another Roche drug, the breast cancer therapy Herceptin, which is generically known as trastuzumab.

Alanna Byrne

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.